Activation of the murine c-myc promoter by murine c-Myb protein was examined in several cell lines by using a transient expression system 
confirmed that the induction of c-myc by c-Myb was transcriptional and affected both P1 and P2 start sites in a murine T-cell line, ELA, and a myelomonocytic line, WEHI-3. Mutational analyses of the c-myc promoter revealed that two distinct regions could confer Myb responsiveness in two T-cell lines, a distal site upstream of P1 and a proximal site within the first noncoding exon. In contrast, only the proximal site was required for other cell lineages examined. Five separate Myb-binding sites were located in this proximal site and found to be important for c-Myb trans activation. DNA binding was necessary for c-myc activation, as shown by the loss of function associated with mutation of Myb's DNA-binding domain and by trans-dominant repressor activity of the DNA binding, trans-activation-defective mutant. The involvement of additional protein factors was addressed by inhibiting protein synthesis with cycloheximide in a conditional expression system in which the activity of presynthesized Myb was under the control of estrogen. These experiments indicate that de novo synthesis of additional proteins was not necessary for c-myc trans activation. Together these data reveal two cell lineage-dependent pathways by which c-Myb regulates c-myc; however, both pathways are mechanistically indistinguishable in that direct DNA binding by Myb is required for activating c-myc whereas neither de novo protein synthesis nor other labile proteins are necessary.
c-myb and c-myc are members of the nuclear protooncogene family (13, 31, 32, 48) . The expression of c-myc mRNA and that of c-myb mRNA are each correlated with cell proliferation and differentiation (13, 31, 32, 48) . Expression of both proto-oncogenes increases dramatically when lymphocytes are induced by mitogens or growth factors to enter the cell cycle (13, 31, 32, 48, 52) . They are expressed at high levels in immature hematopoietic cells (13, 31, 32, 48, 52, 55) and decrease in a biphasic manner during terminal differentiation (11, 12, 33, 34, 47, 53) . Unlike c-myc, which is ubiquitous, c-myb is preferentially expressed in cells of hematopoietic origin, suggesting that c-Myb may be an important regulator of hematopoiesis (13, 31, 32, 48, 55) .
Experimental evidence supports respective roles for each gene product in proliferation or differentiation control. Antisense DNAs (1, 16, 18, 21, 59 ) specific for either gene will inhibit the proliferation of myeloid leukemia cells and T cells. Constitutive overexpression of c-myc or c-myb mRNA in vivo can prevent terminal differentiation in certain cell types (11, 12, 33, 34, 47, 53) or enhance competence for cell cycle progression (14, 54) . Antisense oligonucleotides complementary to c-myb mRNA can inhibit colony formation by hematopoietic progenitor cells in vitro (19) . Likewise, in vivo inactivation of the c-myb gene results in defective hematopoiesis (35) . Recent data demonstrating that c-Myb protein can activate c-myc gene expression (15, 36, 60) suggest that their expression might be functionally linked * Corresponding author. rather than merely parallel. Therefore, it becomes imperative to understand how the Myb protein might regulate c-myc gene expression.
The c-Myb protein and its oncogenic homologs encoded by the avian myeloblastosis virus (AMV) and E26 leukemia virus appear to be transcriptional regulators (15, 24, 26, 37, 39, 46, 57) . These proteins bind to specific DNA sequences, and tandem repeats of these Myb regulatory elements (MREs) will confer Myb-specific regulation to an unresponsive promoter (17, 22, 36, 39, 46, 57, 60) . Likewise, structural domains previously identified by their similarity to known transcription factors have been shown to mediate Myb's activation function (31, 48) . For c-Myb, these domains encode DNA-binding, trans-activator, and negative regulatory functions (22, 25, 26, 28, 45, 46) . The DNAbinding domain is contained within an amino-terminal region consisting of three 50-amino-acid repeats (31, 48) . These consecutive repeats (Rl, R2, and R3) contain a high percentage of basic amino acids and a conserved spacing of relatively rare tryptophan residues (31, 45, 48) . Of the three repeats, only R2 and R3 are required for DNA binding (22, 45, 57) . c-Myb contains a leucine zipper-like structure which may be involved in interaction with other proteins (26) . The leucine zipper is contained within a larger negative regulatory domain whose deletion potentiates Myb's trans-activation function (24, 26, 46) . A trans-activator domain has been localized to an acidic region in the center of the c-Myb protein (26, 46, 57) . Transduced v-Myb proteins are invariably truncated compared with c-Myb and appear to be more potent transcriptional activators (20, 24, 25, 46, 57) . Reten-UP-REGULATION OF c-myc BY Myb IN DIFFERENT CELL LINES 2859 tion of the DNA-binding and trans-activator domain concomitant with loss of the negative regulatory domain or a small amino-terminal domain whose phosphorylation inhibits DNA binding in v-Myb proteins appears to be a key feature in transformation (20, 24-26, 30, 46, 57) .
Several cellular genes whose expression is regulated by Myb have been identified. A current list of Myb-regulated genes includes the human c-myb, lysozyme, Hsp70, mim-1, MD-1, and CD4 genes (9, 28, 39, 40, 51) . The presence of Myb-binding sites in the promoter sequences of the mim-1 and c-myb genes appears, in part, to confer responsiveness to the Myb protein (39, 40) . Other genes may be regulated indirectly. For example, the Hsp7O promoter can be trans activated by DNA binding-defective Myb mutants (28) . Likewise, activation of the MD-1 gene is blocked by protein synthesis inhibitors (9) . Human and murine c-myc also contain Myb-binding sites and are trans activated by c-Myb (15, 36, 60) ; however, a direct link between Myb binding and trans activation has not been established.
In this study, c-myc trans activation by c-Myb was analyzed in several cell lineages and lineage-specific mechanisms were revealed. We further explored the activation pathway in detail and showed that Myb binding to sites within the first exon was required. Neither de novo protein synthesis nor labile protein factors were necessary. We also show that both P1 and P2 transcription was induced by Myb. WEHI-231, L929, and BW5147 cells were all grown in Dulbecco modified Eagle medium-H (DMEM-H) supplemented with 7.5% fetal calf serum, 100 p,g of streptomycin per ml, 100 U of penicillin per ml, 0.1 mg of gentamicin per ml, 1 mM sodium pyruvate, 1 mM nonessential amino acids, 2 mM glutamine, and 5 x 10-5 M 2-mercaptoethanol. 70Z/3, 402AX, CH12.LX2, and PU5.1R cells were grown in RPMI 1640 medium with the same supplements. ETA and WEHI-3 cells were also adapted to growth in phenol red-free DMEM-H.
MATERIALS AND METHODS
Plasmids. Construction of pMBgCAT, pSmBgCAT, pMBgCAT(2-36), pMBgXhCAT, and pMBg96CAT reporter genes has been described elsewhere (2, 44) . pMBgCAT (AAw-Sm) and pMBgCAT(ABx-Sm) were constructed from pMBgCAT by partial digestion with, respectively, the AlwNI and BstXI restriction enzymes, blunt ending the 3' protruding ends with T4 DNA polymerase (Boehringer Mannheim), digestion with SmaI enzyme to release the AlwNISmaI or BstXI-SmaI fragment, and ligation of the vector. Reporter genes pMBg(AHd-Xh), pMBg(AHd-Nt), and pMBg(ANt-Xh) were prepared from pMBgCAT by digestion with the HindIII, NotI, orXhoI restriction enzyme to release the corresponding HindIII-XhoI, HindIII-NotI, or NotIXhoI fragment; blunt ending the 5' protruding ends with Klenow polymerase (Boehringer Mannheim); and vector ligation. pSmBg(AHd-Xh) and pSmBg(ANt-Xh) are the corresponding deletions made in pSmBgCAT. pSVM(H)RCAT contains the HindIII-BglII first exon fragment of c-myc cloned downstream of the simian virus 40 (SV40) promoter.
The c-myc fragment contains 24 bp 5' of the P2 initiation site but lacks the TATA box positioned 28 to 32 bp 5' of this start site. Previous work has shown that the P2 start site is silent and that transcription initiates from El and E2 start sites of the SV40 promoter (58) .
Site-specific mutants of putative Myb-binding sites 11 to 15 were made by Kunkel mutagenesis. Briefly, the BglIIBglII fragment of the murine c-myc promoter was subcloned into the BglII site of pSG5 (Stratagene). Template strands of c-myc were prepared by M13K07 helper phage rescue in Dut-Ung-CJ236 bacteria. Mutant oligonucleotides were annealed, and second-strand synthesis was completed with T4 DNA polymerase and deoxynucleoside triphosphates.
Circular templates were transformed into DHSa bacteria, and mutant sequences were confirmed by dideoxy sequencing. The BglII-BglII fragment containing mutant Myb sites was subcloned into pCAT(AEP) for transient transfections.
The wild-type Myb expression vector pRmb3SVneo and frameshift mutant pJTmyb-fs were constructed as described previously (15, 33) . pJTmyb-fs lacks 7 bp 3' to the BstXI site pNEO-AMV is an AMV v-myb expression vector which contains a provirus, and its transcription is driven by the long terminal repeat (25) . pNEO-MAV-CLA is a control plasmid in which the KYnI-XbaI v-myb fragment of pNEO-AMV has been deleted and replaced by a ClaI linker (25) . pNEO-Myb-E is a v-myb-estrogen receptor fusion vector in which the hormone-binding domain of the human estrogen receptor has been fused in frame at the BalI site. The carboxyl-terminal 16 amino acids of v-Myb was deleted in this process. pNEO-Myb-E was derived from Neo-AMV-AGE (25) and lacks gag and env sequences.
The pBS-globin plasmid (a gift of F. Fumari, University of North Carolina) was constructed by inserting a blunt-ended 2.2-kb HindIII-XbaI fragment of pSP64HDB6 (29) which contained the genomic sequence for the 3-globin gene into the SmaI site of pBS+ (Stratagene). The murine c-myc promoter was cloned into pBS-globin in two steps to make pMyc-globin as follows. The BglII-BglII c-myc promoter fragment from pMBgCAT was isolated, blunt ended with Klenow polymerase, and ligated into the HincIl site of pBS+ (Stratagene). The c-myc promoter was subsequently removed as two fragments, XbaI-HindIII and HindIIIHindIII, by digestion with XbaI and HindIII restriction enzymes. Both fragments were ligated into the XbaI to HindIII site of pBS-globin, and directional ligation was confirmed by restriction mapping and double-stranded dideoxy sequencing.
Transient transfections and chloramphenicol acetyltransferase (CAT) assays. All cells were seeded at low densities and grown to log phase over 48 h prior to transfection.
Subconfluent monolayers of adherent WEHI-3, PU5-1.8, and C33 cells were used. The cells were transfected with a Bio-Rad gene pulser as described elsewhere (50) . Transfec-VOL. 13, 1993 on (50) . The average enzyme assay was 1 to 2 h for EM4 and 4 to 24 h for other cell lines. Percent acetylation was quantified by cutting out sections of the thin-layer chromatography plate that corresponded to these two forms, followed by scintillation counting. RNA isolation and Si nuclease protection analysis. Cells were harvested for RNA preparation 24 h posttransfection. Total cellular RNA was recovered by lysis of transfected cells in guanidine-thiocyanate and pelleting through CsCl as described elsewhere (10) . Uniformly labeled antisense probes for murine c-myc were prepared by primer extension of a single-stranded DNA template copy of the pMyc-globin reporter plasmid. Template sense strands of pMyc-globin were prepared by M13KO7 helper phage rescue. The globin-2 primer 5'-CAGTAACGGCAGACTTG-3' was annealed to the first exon of human globin sequence, and extension was carried out with Klenow polymerase using [cc-32P]dATP, [a-32P]dCTP, and unlabeled dGTP and dTrP.
After digestion with SmaI, the strands were separated on a 4% denaturing polyacrylamide-urea gel. Probe bands were excised and eluted in 0.5 M sodium acetate-0.1% sodium dodecyl sulfate solution. Annealing reactions were set up with 100,000 cpm of antisense DNA probe and 30 p,g of RNA, and hybridization reactions were carried out overnight at 58°C in a solution of 80% formamide, 40 mM PIPES [piperzidine-N,N'-bis(2-ethanesulfonic acid)], 400 mM NaCl, and 1 mM EDTA. Samples were digested with 400 U of S1 nuclease (Bethesda Research Laboratories) as described previously (6) and then electrophoresed through a 4% denaturing polyacrylamide-urea gel along with HaeIII-cut pBR322 markers. Protected bands were detected by autoradiography. no. E-2758). To determine the need for de novo protein synthesis in Myb function, estrogen-dependent activation of the Myb-estrogen receptor fusion protein was measured in the presence of the protein synthesis inhibitor cycloheximide. Cycloheximide was added 20 min prior to estrogen induction to a final concentration of 50 p,g/ml, which inhibited protein synthesis virtually completely as measured by
[35S]methionine incorporation (data not shown). Cells were treated with estrogen and cycloheximide either alone or in combination for 5 h prior to RNA preparation. Changes in c-myc promoter activity were measured by S1 nuclease protection analyses from the cotransfected pMyc-globin plasmid.
RESULTS
The magnitude of Myb activation of the c-myc gene is cell type dependent. Previously, we showed that a Rous sarcoma virus long terminal repeat-driven c-Myb expression vector could activate a 1.7-kb c-myc promoter fragment linked to a CAT reporter gene in T cells (15) . To determine whether the trans activation of c-myc by c-Myb occurs in different cell types, we examined the panel of murine cell lines shown in Table 1 . These plasmids were introduced at a 1:1 ratio and in one case at a 4:1 ratio of the Myb expression vector to pMBgCAT. Myb trans activation of c-myc (expressed as fold trans activation) was normalized both to a frameshift mutant of the Myb expression vector and to a promoterless reporter gene. (Table  1) . Moderate responses were seen in four lymphoid lines from B and T lineages (6-to 10-fold). The strongest responses were elicited in two myelomonocytic cell lines (20-to 30-fold), suggesting that myelomonocytic cells are especially permissive for this activation pathway.
The best activation was seen in cell lines which express low endogenous levels of c-Myb, such as our WEHI-3 and ELA lines. Background transcription due to endogenous Myb is not high enough to interfere with trans activation.
70Z/3 pre-B cells contain high endogenous levels of c-myb which may contribute to the poor trans activation at the standard 1:1 ratio of Myb to c-myc. Higher concentrations of c-Myb (at a 4:1 ratio) did result in sixfold trans activation. To exclude the possibility that the magnitude of activation varied with amount of c-Myb produced from the expression vector, Myb proteins were immunoprecipitated from transfected cell lines. Transfected Myb protein was efficiently produced in even poorly responding cell lines such as 402AX (data not shown). We conclude that the cell type influences how well Myb activates c-myc.
Myb induces expression of Pl-and P2-initiated c-myc transcripts. The above results represent the measurement of CAT protein which may reflect changes in both RNA and protein levels. Here, we determined whether Myb activation caused specific increases in the levels of accurately initiated c-myc mRNAs and, if so, whether these increases were preferential for P1-or P2-initiated transcripts and whether they varied with cell lineage. We have found that CAT messages are unstable; hence, we cloned the 1.7-kb c-myc promoter fragment into a P-globin test plasmid for the purpose of stabilizing mRNA accumulation (3). This test plasmid was transfected into ETA T cells or WEHI-3 myelomonocytic cells with full-length or frameshift mutant Myb expression vectors. The RNA was isolated, and Si nuclease protection was used to detect levels of endogenous and plasmid-derived c-myc mRNAs. Plasmid-derived transcripts were distinguished from endogenous c-myc transcripts by an additional 118 bp of ,-globin sequence protected in the RNA-DNA probe hybrids. A map of pMyc-globin and resulting S1 hybrids is shown at the top of Fig. 1 . Autoradiography from short (lanes 1 to 3 and 7 to 9) and long (lanes 4 to 6 and 10 to 12) exposures is shown to better reveal changes in P2 and P1 transcript levels, respectively, because the P2 signal is much stronger than the P1 signal (bottom of Fig. 1 ).
Myb effectively induced expression of c-myc mRNAs from the cotransfected pMyc-globin plasmid in EL4 cells (compare Myb-induced results in lanes 2 and 5 with uninduced results in lanes 1 and 4, respectively). Cells transfected with a promoterless pBS-globin test plasmid did not express Myc-globin transcripts, as expected (lanes 3 and 6). Both P1 and P2 transcripts were induced by Myb. While it is clear that both authentic transcripts are induced from the test plasmid, changes in the expression of endogenous c-myc gene were not detected, most likely because the transfected cells, and hence Myb-induced transcripts, represent a small fraction of the total cells. WEVEII-3 cells were also studied since myelomonocytic cells are the preferred targets for Myb transformation in chickens (25, 31, 48) and because c-myc was effectively activated by Myb in these cells (Table 1) . Identical increases in P1 and P2 transcript levels were observed (Fig. 1, lanes 7 to 12) .
Since the Myb-induced accumulation of c-myc mRNAs could be regulated at the level of RNA stability, we inhibited FIG. 1. S1 nuclease protection assay of Myb-induced mRNAs in EIA and WEHI-3 cells. A map of the pMyc-globin reporter plasmid is shown at the top. Bg, BglII; Sm, SmaI. The dotted arrow represents the labeled primer extension product used in hybridization to transiently expressed mRNAs. S1 nuclease digestion yields mRNA-probe hybrids of various lengths which are represented by lines and labeled on the autoradiograph. Lanes 1 to 6 are samples from EL-4 cells, and lanes 7 to 12 are samples from WEHI-3 cells. pMyc-globin reporter was included in lanes 1, 2, 4, 5, 7, 8, 10, and 11, and control reporter pBS-globin was included in lanes 3, 6, 9, and 12. The wild-type Myb expression vector, pRmb3SVneo, was included in lanes 2, 3, 5, 6, 8, 9, 11, and 12, and frameshift mutant vector pJTmyb-fs was included in lanes 1, 4, 7, and 10. The autoradiograph was exposed for 5 days in lanes 1 to 3 and 7 to 9 and 2 weeks in lanes 4 to 6 and 10 to 12.
transcription with actinomycin D and compared the decay of Myb-stimulated and unstimulated transcripts. The Mybinduced transcripts from the test plasmid appeared to decay with the same half-life (approximately 2 h) as noninduced transcripts, suggesting that Myb induces c-myc transcription (data not shown).
Deletion mapping of the murine c-myc promoter reveals proximal and distal Myb response regions (MRRs) in the lymphoid cell line EL4. Our analysis for potential MREs revealed 16 potential sites spread throughout the murine c-myc promoter which contain the critical AAC motif contained in all Myb-binding sites (7, 23, 37, 56, 60) . Ten Myb-binding sites were located upstream of the P1 start site, and six were located downstream of the P2 start site (numbered 1 to 16 in Fig. 2 ). Sites 3, 9, and 10 are perfect matches to one of the three consensus sequences (7, 23, 37 (2) which showed that this same deletion increases the constitutive activity of the P1 promoter. It is likely that P1 compensates for the P2 deletion.
To further localize the response region within the first exon, either half of this + 148 to +515 region was deleted. In this representative experiment (Fig. 3B) , deletion of either half had no significant effect compared with deletion of both halves, which was only 33% as active as the wild type. These data suggest that either half can compensate for the other, as confirmed by later mutagenesis studies (see Tables 2 and 3 ). In Fig. 3B , deletion of the distal MRR between bp -1140 and -424 (pSmBgCAT plasmid) increased background transcription as it decreased Myb induction. This effect was consistent for three different DNA preparations and may reflect the deletion of a lymphoid-specific dehancer element previously mapped to this region (44) . The dual use of a distal and a proximal response region was also observed in another T-cell line, BW5147 (Table 1 ). These data suggest that the Myb activation of c-myc in T-cell lines requires two MRRs: (i) a distal site upstream of the P1 promoter between bp -868 and -424 and (ii) a proximal site including first-exon sequences between bp +148 and +515.
Deletion mapping in myelomonocytic WEHI-3 cells reveals exclusive utilization of the proximal response region. To determine whether the same MRRs were utilized in other responder cell types, deletions of the 1.7-kb c-myc fragment in the pMBgCAT reporter plasmid were assayed for Myb responsiveness. The myelomonocytic cell line WEHI-3 was again chosen as an interesting model. As shown in Fig. 4A , the wild-type pMBgCAT reporter plasmid was stimulated >30-fold by c-Myb. Unexpectedly, truncation of the distal bp -1140 to -424 region which defines a distal MRR in EMA cells had no effect on WEHI-3 cells. This observation was confirmed four times. The MRR in WEHI-3 cells could be mapped to the first noncoding exon, as shown by Myb's ability to activate the pMBmBgCAT plasmid, which contains the first exon, but not the exonless pMSmBmCAT plasmid (Fig. 4A) .
To determine whether the MRR in the first exon mapped to the same proximal bp +148 to +515 site utilized in ELM cells, the corresponding HindIII-XhoI segment was deleted and shown to cause a significant loss (95%) of Myb responsiveness (Fig. 4B) . Deletion of either half of this region produced little effect, similar to EM4 cells. The utilization of the -1140 to -424 distal MRR in EML and BW5147 cells but not WEHI-3 cells suggests that Myb activates through this distal site in a T-cell-specific manner. All other cell types examined require only the proximal response region of c-myc for c-Myb trans activation ( Table 1) . The first exon of c-myc is sufficient to confer Myb responsiveness to a heterologous promoter in WEHI-3 cells but not ELA cells. Since the proximal site appeared to be an important MRR in all cell types, this region was separated from the rest of the c-myc promoter and tested for its ability to confer Myb responsiveness to an enhancerless test plasmid. The plasmid pSVM(H)RCAT contains the HindIII-to-BglII fragment of c-myc's first exon cloned in its natural orientation downstream of the SV40 promoter. Myb induction of the pSVM(H)RCAT reporter plasmid was compared between EMA and WEHI-3 cells ( Site-specific mutagenesis of potential Myb-binding sites. To finely map the MREs in the c-myc promoter, potential Myb-binding sites from Fig. 2 were selected and mutated.
This endeavor has been fraught with difficulties because of the large number of potential c-Myb-binding sites in this promoter. Furthermore, mutation of single or even a few sites has little effect on c-Myb trans activation (see below). Most of the efforts have been devoted to the Myb target sites in the first exonic region because (i) this region is important in all cell types tested, (ii) the effect is consistently large and not variable between experiments, and (iii) fewer c-Myb targets are involved, making the mutagenesis scheme more feasible. Five different potential sites were identified (sites 11 to 15 in Fig. 2 ) in this region. In three different experiments with EIA cells, significant residual activity was observed when one to four of these sites were mutated, and mutation of all five sites was essential for the near obliteration of Myb trans-activating activity (Tables 2 and 3 ). This strongly suggests that many of these sites may be redundant and agrees with data shown earlier in Fig. 3B Figure 6A shows the c-Myb protein with the locations of its three regulatory domains: the DNA-binding domain, the trans-activator domain, and the negative regulatory domain. ATA contains an internal deletion of the trans activator domain. ABALI has a carboxyl-terminal truncation which removes the trans activator domain but retains the DNA-binding domain. W-G contains a point mutation which replaces the last tryptophan in the R3 domain (amino acid 185) with a glycine and affects the ability of this mutant protein to bind DNA (45) .
EL4 cells were transfected with the wild-type or mutant Myb expression vectors and pMBgCAT, and the results of three experiments were averaged (Fig. 6B) . The wild-type expression vector, pRmb3SVneo, elicited 23.4-and 51.5-fold activations at 1:1 and 2:1 ratios of Myb expression vector pMBgCAT, respectively. pMBgCAT was trans activated only twofold by the W-G mutant, suggesting that trans activation was dependent on DNA-binding function. ATA was approximately 15% as active as wild-type Myb expression vector. The significant eightfold activation at the 2:1 ratio suggests that other regions of the protein may have weak trans-activator function or that Myb function is coupled to other proteins with activator function in EM4 cells. The expression of all the mutant proteins was confirmed by immunoprecipitation analyses (data not shown). Parallel studies with WEHI-3 cells showed similar requirements for the DNA-binding and trans-activator domains with the following exception: ATA was not able to trans activate c-myc at all in WEHI-3 cells (data not shown).
To independently assess the necessity for DNA binding in c-myc activation, nonfunctional mutants ABALI and W--G were cotransfected with pRmb3SVneo into EL4 and assessed for their ability to trans-dominantly repress activation by wild-type Myb protein (Fig. 6C) . The ABALI mutant, which encodes the DNA-binding domain of c-Myb, would be expected to produce proteins which saturate DNA-binding sites in vivo and prevent binding by wild-type c-Myb protein. In two independent experiments, ABALI repressed activation by wild-type c-Myb to 52 and 27% of control values; the average result of both experiments (39% of wild-type) is shown. W--G had no effect in either experi- Maps of the wild-type pMBgCAT reporter plasmid, heterologous promoter test plasmid pSVM(H)RCAT, and control enhancerless SV40 promoter are shown. Bg, BglII; Hd, HindIll. These reporter genes were cotransfected at 1:1 ratios with wild-type or frameshift mutant Myb expression vectors. Myb-specific transactivations elicited in EL4 and WEHI-3 cells were calculated as described in the legend to Fig. 3 Fig. 7B . In EL4 cells, a 5-h estrogen induction induced approximate fourfold and twofold increases in P1-and P2-initiated c-myc transcripts, respectively, as determined by densitometric measurements (Fig. 7B, lane 1 versus lane 2) . This degree of induction was lower than that observed in Fig. 1 because some Myb protein was made in the absence of estrogen induction, thus contributing to a high baseline. Nonetheless, treatment with cycloheximide did not significantly affect the level of c-myc (Fig. 7B, lane 3) . Induction with estrogen in the presence of cycloheximide resulted in equivalent enhancement of mRNA levels to those of the samples treated with cycloheximide alone (lane 4). Again, the Myb protein appeared not to affect endogenous c-myc levels (lanes 1 to 4). These data indicated that Myb induction in EL4 cells does not require additional de novo protein synthesis. Similar studies were performed with WEHI-3 cells with similar results (data not shown).
DISCUSSION
Myb activation of c-myc gene expression involves a potentially important regulatory cascade in vivo between two proto-oncogene transcription factors. Myb and Myc each share a common function in that they control cell proliferation and differentiation (13, 31, 32, 48 (28) , and for the MD-1 gene, in which de novo protein synthesis is required for Myb regulation (9) . For this reason we used a conditional system to test whether Myb could activate c-myc in the absence of de novo protein synthesis (Fig. 7) . These data suggest that Myb can activate c-myc in the absence of de novo protein synthesis and that labile proteins which modulate basal c-myc transcription are not linked to the Myb activation pathway (38) . These experiments do not rule out cofactors with long half-lives. We suggest that if these cofactors exist, they are cell specific and influence how Myb interfaces with c-myc. These factors may modify Myb itself by posttranslational modification or behave as coactivator proteins on the c-myc promoter.
Which c-myc transcripts are induced by Myb has not been reported previously. In this paper we show that c-Myb appears to show little promoter preference in activating c-myc transcription. Previous work suggests that the P1 and P2 promoters of c-myc are regulated independently (2, 58) . Elements within the first 100 bp upstream of P1 affect P1 activity, while elements in the first exon sequence upstream of P2 affect P2 activity (2) . While elements upstream of P1 pNEO-MAV-CLA pNEO-AMV pNEO-Myb-E A VOL. 13, 1993 on January 4, 2018 by guest http://mcb.asm.org/ would be expected to influence P1 transcription, the findings that WEHI-3 cells utilize only the proximal MRR and that Myb stimulates both P1 and P2 transcripts suggest that elements downstream of P2 affect both promoters. This is consistent with previous evidence showing that the first exon contains a position-and orientation-dependent element which can promote transcription from both the El and E2 start sites of the SV40 promoter contained in the pSVM(H)R-CAT test plasmid (58) . It is possible that Myb regulates the function of this positive control element.
In conclusion, this report shows that activation of the P1 and P2 promoters of murine c-myc by Myb is dependent on a distal upstream region and DNA within the first exon of c-myc in T cells while only the first exon region is necessary in other cells. Both 
